title: 2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis.
abstract: OBJECTIVE
  To update the evidence-based position statement published by the French National Authority for Health (HAS) in 2006 regarding the pharmacological treatment of postmenopausal osteoporosis, under the auspices of the French Society for Rheumatology and Groupe de Recherche et d'Information sur les Ostéoporoses (GRIO), and with the participation of several learned societies (Collège National des Gynécologues et Obstétriciens Français, Groupe d'Étude de la Ménopause et du Vieillissement hormonal, Société Française de Chirurgie Orthopédique, Société Française d'Endocrinologie, and Société Française de Gériatrie et de Gérontologie).
  
  
  METHODS
  A multidisciplinary panel representing the spectrum of clinical specialties involved in managing patients with postmenopausal osteoporosis developed updated recommendations based on a systematic literature review conducted according to the method advocated by the HAS.
  
  
  RESULTS
  The updated recommendations underline the need for osteoporosis pharmacotherapy in women with a history of severe osteoporotic fracture. In these patients, any osteoporosis medication can be used; however, zoledronic acid is the preferred first-line medication after a hip fracture. In patients with non-severe fractures or no fractures, the appropriateness of osteoporosis pharmacotherapy depends on the bone mineral density and FRAX(®) values; any osteoporosis medication can be used, but raloxifene and ibandronate should be reserved for patients at low risk for peripheral fractures. Initially, osteoporosis pharmacotherapy should be prescribed for 5 years. The results of the evaluation done at the end of the 5-year period determine whether further treatment is in order.
  
  
  CONCLUSIONS
  These updated recommendations are intended to provide clinicians with clarifications about the pharmacological treatment of osteoporosis.
authors.affiliation: Service de rhumatologie, hôpital Cochin, université Paris-Descartes, Paris, France. karine.briot@cch.aphp.fr
authors.forename: Karine
authors.initials: K
authors.lastname: Briot
authors.forename: Bernard
authors.initials: B
authors.lastname: Cortet
authors.forename: Thierry
authors.initials: T
authors.lastname: Thomas
authors.forename: Maurice
authors.initials: M
authors.lastname: Audran
authors.forename: Hubert
authors.initials: H
authors.lastname: Blain
authors.forename: Véronique
authors.initials: V
authors.lastname: Breuil
authors.forename: Laure
authors.initials: L
authors.lastname: Chapuis
authors.forename: Roland
authors.initials: R
authors.lastname: Chapurlat
authors.forename: Patrice
authors.initials: P
authors.lastname: Fardellone
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Feron
authors.forename: Jean-Bernard
authors.initials: JB
authors.lastname: Gauvain
authors.forename: Pascal
authors.initials: P
authors.lastname: Guggenbuhl
authors.forename: Sami
authors.initials: S
authors.lastname: Kolta
authors.forename: Eric
authors.initials: E
authors.lastname: Lespessailles
authors.forename: Brigitte
authors.initials: B
authors.lastname: Letombe
authors.forename: Christian
authors.initials: C
authors.lastname: Marcelli
authors.forename: Philippe
authors.initials: P
authors.lastname: Orcel
authors.forename: Patrick
authors.initials: P
authors.lastname: Seret
authors.forename: Florence
authors.initials: F
authors.lastname: Trémollières
authors.forename: Christian
authors.initials: C
authors.lastname: Roux
mesh_terms: D000328:Adult; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine / Q000592:standards*; D005260:Female; D050723:Fractures, Bone / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000517:prevention & control*; D005602:France / Q000453:epidemiology; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000453:epidemiology; D017410:Practice Guidelines as Topic / Q000592:standards*; D011859:Radiography; D012307:Risk Factors
chemical_list: D050071:Bone Density Conservation Agents